While HMA treatment alone still has very limited activity against AML, AZA has become indispensable as a combination partner for the BCL2-inhibitor venetoclax (VEN) or the IDH1 inhibitor ivosidenib (IVO, see below). This evidence concerns the gene BCL2 and acute myeloid leukemia.